Gesynta Pharma Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$36.8M
- Investors
-
16
Gesynta Pharma General Information
Description
Developer of a clinical-stage pharmaceutical portfolio designed to treat inflammatory diseases by inhibiting pro-inflammatory pathways. The company offers selective enzyme-targeting drug candidates with favorable safety and pharmacological profiles, enabling patients with inflammatory conditions such as endometriosis to experience non-hormonal symptom relief and improved quality of life.
Contact Information
Website
www.gesynta.seCorporate Office
- Wallingatan 24
- 111 24 Stockholm
- Sweden
Corporate Office
- Wallingatan 24
- 111 24 Stockholm
- Sweden
Gesynta Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series B) | 21-Oct-2025 | $36.8M | Completed | Clinical Trials - Phase 2 | ||
| 8. Early Stage VC | 31-Dec-2021 | Completed | Clinical Trials - General | |||
| 7. Early Stage VC | 07-Jul-2020 | Completed | Clinical Trials - General | |||
| 6. Seed Round | 04-Apr-2019 | Completed | Startup | |||
| 5. Grant | 01-Dec-2018 | Completed | Startup | |||
| 4. Grant | 18-May-2018 | Completed | Startup | |||
| 3. Accelerator/Incubator | 27-Apr-2018 | Completed | Startup | |||
| 2. Angel (individual) | 26-Feb-2018 | $2.9M | $2.9M | Completed | Startup | |
| 1. Accelerator/Incubator | 01-Jan-2018 | Completed | Startup |
Gesynta Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 90,091 | $74.19 | $74.19 | 1x | $74.19 | 24.27% | ||
| Ordinary | 38,747 | $65.85 | $65.85 | 1x | $65.85 | 10.44% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Gesynta Pharma Comparisons
Industry
Financing
Details
Gesynta Pharma Competitors (15)
One of Gesynta Pharma’s 15 competitors is Hope Medicine, a Venture Capital-Backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Hope Medicine | Venture Capital-Backed | Shanghai, China | ||||
| Onconova Therapeutics | Formerly VC-backed | Newtown, PA | ||||
| Neurocrine Biosciences | Formerly VC-backed | San Diego, CA | ||||
| GeneScience Pharmaceutical | Corporation | Changchun, China | ||||
| Nippon Shinyaku | Corporation | Kyoto, Japan |
Gesynta Pharma Patents
Gesynta Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202510775-D0 | New treatment methods | Pending | 03-Jul-2025 | ||
| AU-2023332204-A1 | Methods for the treatment or prophylaxis of endometriosis | Pending | 01-Sep-2022 | ||
| EP-4580625-A1 | Methods for the treatment or prophylaxis of endometriosis | Pending | 01-Sep-2022 | ||
| US-20260146029-A1 | Methods for the treatment or prophylaxis of endometriosis | Pending | 01-Sep-2022 | ||
| WO-2024047229-A1 | Methods for the treatment or prophylaxis of endometriosis | Inactive | 01-Sep-2022 | A61K31/4184 |
Gesynta Pharma Signals
Gesynta Pharma Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amboy Street Ventures | Venture Capital | Minority | ||
| Catalyze-Capital | Venture Capital | Minority | ||
| CTI Life Sciences Fund | Venture Capital | Minority | ||
| Foreground Capital | Venture Capital | Minority | ||
| HealthCap | Venture Capital | Minority |
Gesynta Pharma Investments (1)
Gesynta Pharma’s most recent deal was a Corporate Asset Purchase with Orexo (OX-MPI Project). The deal was made on 29-Sep-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Orexo (OX-MPI Project) | 29-Sep-2017 | Corporate Asset Purchase | Buildings and Property |
Gesynta Pharma FAQs
-
When was Gesynta Pharma founded?
Gesynta Pharma was founded in 2017.
-
Where is Gesynta Pharma headquartered?
Gesynta Pharma is headquartered in Stockholm, Sweden.
-
What is the size of Gesynta Pharma?
Gesynta Pharma has 11 total employees.
-
What industry is Gesynta Pharma in?
Gesynta Pharma’s primary industry is Drug Discovery.
-
Is Gesynta Pharma a private or public company?
Gesynta Pharma is a Private company.
-
What is Gesynta Pharma’s current revenue?
The current revenue for Gesynta Pharma is .
-
How much funding has Gesynta Pharma raised over time?
Gesynta Pharma has raised $77.9M.
-
Who are Gesynta Pharma’s investors?
Amboy Street Ventures, Catalyze-Capital, CTI Life Sciences Fund, Foreground Capital, and HealthCap are 5 of 16 investors who have invested in Gesynta Pharma.
-
Who are Gesynta Pharma’s competitors?
Hope Medicine, Onconova Therapeutics, Neurocrine Biosciences, GeneScience Pharmaceutical, and Nippon Shinyaku are some of the 15 competitors of Gesynta Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process